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Edited by Gianni CesareniAbstract PRMT7 belongs to the protein arginine methyl-trans-
ferases family. We show that downregulation of PRMT7a and b
isoforms in DC-3F hamster cells was associated with increased
sensitivity to the Top1 inhibitor camptothecin (CPT). This eﬀect
was not due to a change in Top1 contents or catalytic activity, or
to a diﬀerence in the reversal of DNA breaks. Overexpression of
PRMT7a and b in DC-3F cells had no eﬀect on CPT sensitivity,
whereas it conferred a resistance to DC-3F/9-OH-E cells for
which both isoforms are reduced by two- to three-fold as com-
pared to DC-3F parental cells. Finally, downregulation of the
human PRMT7 could also sensitize HeLa cells to CPT, suggest-
ing that it could be used as a target to potentiate CPT deriva-
tives.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Resistance1. Introduction
DNA topoisomerase I (Top1) is a nuclear enzyme that plays
a crucial role during replication and transcription by removing
torsionnal constraints associated with forks progression [1].
Top1 inhibitors such as camptothecins induce the formation
of cytotoxic DNA strand breaks which result from the ‘‘stabil-
ization’’ of Top1–DNA covalent cleavage complexes by the
drug [2,3]. Camptothecin derivatives have been successfully
developed for the treatment of lung, ovary and colon cancers,
but their clinical use is still limited by the emergence of resis-
tance mechanisms involving a variety of genes involved in mul-
tiple pathways including drug metabolism, cell cycle control,
DNA damage signalling, DNA repair, and apoptosis [4,5].
Functional screening approaches such as the genetic suppres-
sor elements (GSE) strategy have been developed to identify
genes playing a key role in the cellular sensitivity to various
anticancer agents, including topoisomerase inhibitors [6–12].
GSEs are small cDNA fragments that can confer resistance*Corresponding author. Tel.: +33 5 56 33 04 29; fax: +33 5 56 33 32 06.
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corresponding genes [10]. This methodology allowed the iden-
tiﬁcation of 11 GSEs confering a resistant phenotype to 9-
hydroxyellipticine, a topoisomerase II inhibitor [6]. Among
them, GSE1 was the most frequently represented in resistant
clones emerging from the selection. It could also confer resis-
tance to other Top2 inhibitors such as etoposide and to cis-
platin. Unexpectedly, GSE1 conferred a hypersensitivity to
other DNA damaging agents such as bleomycin, UV or the
Top1 inhibitor camptothecin.
In DC-3F hamster cells, GSE1 was shown to inhibit the
expression of two proteins of 77 and 82 kDa corresponding
to PMRT7a and b, two isoforms of a novel class of protein
arginine N-methyl transferase. PRMTs are a family of enzymes
involved in the regulation of various cellular processes such as
signal transduction, gene regulation, chromatin remodeling
and RNA splicing [13–17]. They can methylate nitrogen atoms
of the guanidinium side chain of arginines. Type I PMRTs
methylate two diﬀerent nitrogens leading to asymmetric dime-
thylarginines, whereas type II enzymes form symmetric dime-
thylarginines. To date, 9 PRMTs have been identiﬁed in
human [18]. The human PMRT7 belongs to the type II family
of PMRTs and can methylate some known substrates of
PMRT5 including histone H2A and H4 in vitro [19,20]. More
recently, in Xenopus oocytes, its activity was shown to be stim-
ulated by CTCFL, a paralog of the CCCTC-binding factor
[21].
In this study, we evaluated the potential link between
PRMT7a and PRMT7b and the sensitivity of DC-3F hamster
cells to CPT. We found that GSE1-mediated downregulation
of PRMT7a and/or PRMT7b was associated with an in-
creased sensitivity of DC-3F cells to CPT and an increase in
apoptosis. This eﬀect was neither due to a change in Top1
content or catalytic activity, nor it was due to a change in
the reversal of CPT-mediated DNA lesions. CPT sensitivity
of DC-3F cells was not aﬀected by overexpression of
PRMT7a and/or PRMT7b, whereas it was reduced by
approximately two-fold in DC-3F/9-OH-E resistant cells,
which are characterized by a two- to three-fold reduction in
both isoforms. This reduction was also accompanied by a re-
duced level of apoptosis. We showed that reduction of
PMRT7 in human HeLa cells is also correlated with higher
sensitivity to CPT, conﬁrming that PMRT7 could be a poten-
tial target in the sensitization of tumor cells to CPT deriva-
tives used in the clinic.blished by Elsevier B.V. All rights reserved.
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2.1. Cell cultures, chemicals and enzymes
The chinese hamster DC-3F cells were cultured in MEM (Invitro-
gen, Cergy Pontoise, France) containing 10% foetal calf serum (FCS)
in 5% CO2 and 37 C. The DC-3F/9-OH-E resistant cells were ob-
tained by continuous exposure of DC-3F cells to 9-OH-E [22]. HeLa
cells, were grown in DMEM (Invitrogen, Cergy Pontoise, France) with
10% FCS in 5% CO2 at 37 C. Camptothecin (CPT), tetramethylrhod-
amine methylester (TMRM) and verapamil hydrochloride were pur-
chased from Sigma. 9-OH-E was purchased from Calbiochem (La
Jolla, CA). [a32P]-cordycepin was purchased from Perkin–Elmer Life
Sciences Inc. (Courtaboeuf). [2-14C]-thymidine was purchased from
Amersham (Saclay). Terminal deoxynucleotidyl transferase (TdT)
was purchased from Invitrogen. Puriﬁed human Top1 was a kind gift
from Dr. Y. Pommier (NCI, Bethesda, MD). Cell transfections were
performed using the Exgen 500 reagent (Euromedex) according to
the manufacturers protocol.
2.2. Cytotoxicity assays
Drug sensitivity of DC-3F and DC-3F/9-OH-E hamster cell lines
was measured by clonogenic assays. 106 cells were plated in 100 cm2
culture dishes and treated the day after with CPT for 24 h. Cells were
washed three times with PBS, trypsinized, resuspended in fresh med-
ium and reseeded in a new dish. Clones were then visualized by stain-
ing with 1% crystal violet. Untreated cells were also plated as seeding
controls (500 cells/dish).
In some experiments, overexpression of PRMT7 isoforms were per-
formed using the bicistronic plasmids pSV IRES Neo/p78, pSV IRES
Neo/p82 or the empty vector pSV IRES Neo [6]. Transfections were
performed on exponentially growing cells with the Exgen 500 reagent
for 48 h according to the manufacturers protocol. CPT cytotoxicity
was then evaluated by clonogenic assay as indicated above.
Induction of apoptosis was quantiﬁed by ﬂow cytometry by measur-
ing the mitochondrial membrane potential using TMRM. 3 · 105 cells
were plated in 24-well plates, treated with CPT for 24 h. Cells were
then washed with PBS and incubated for 20 min at 37 C in HBSS buf-
fer (NaCl 140 mM, KCl 5 mM, Na2HPO4 0.3 mM, KH2PO4 0.4 mM,
MgCl2 2 mM, CaCl2 2 mM, HEPES 10 mM, glucose 5 mM, NaHCO3
4 mM, pH 7.3) containing 200 nM TMRM and 20 lM verapamil to
avoid any active eﬄux of TMRM. Cells were then trypsinized and ana-
lyzed on a Becton Dickinson FACScan (Becton Dickinson Immunocy-
tometry Systems, San Jose, CA). Statistical analyses were performed
using the Student t-test.
2.3. SiRNA-mediated knockdown of human PRMT7
The SMARTpool siRNAs targeted to human PRMT7 (L-005030-
00), and the non-targeting control siRNA (D-001210-01-20) were pur-
chased from Dharmacon (Lafayette, CO). HeLa cells were seeded at
300000 cells per well in a six-well plate 1 day prior to transfection. siR-
NAs were transfected according to the manufacturers protocol using
3 ll of Oligofectamine transfection reagent (Invitrogen) in 500 ll ﬁnal
volume. Knockdowns were systematically veriﬁed by Western blotting
48 h after transfection.
2.4. Preparation of extracts and Western blot analysis
For nuclear extracts, 108 cells were collected in cold saline contain-
ing 0.02% EDTA and centrifuged at 1500 · g for 5 min at 4 C. Cells
were resuspended in ice-cold hypotonic buﬀer (10 mM Tris/HCl, pH
7.4 containing 10 mM NaCl, 3 mM MgCl2, 0,5% Nonidet P40) con-
taining standard protease inhibitors. Nuclei were isolated after Dounce
homogeneization, pelleted at 1500 · g for 5 min at 4 C, resuspended in
1 ml of hypertonic buﬀer at pH 6.5 (2 mM K2HPO4, 5 mM MgCl2,
1 mM EGTA, 0.1 mM dithiothreitol, 0.35 M NaCl) with proteases
inhibitors. Extraction was performed by rotation of the tubes for 1 h
at 4 C. After centrifugation at 19000 · g for 45 min at 4 C, superna-
tants were collected and protein concentrations were measured. For
whole-cell lysates, cells were incubated in lysis buﬀer (150 mM NaCl,
0.1% SDS, 50 mM Tris, pH 8.0, 0.1% SDS, 0.5% sodium deoxycholate,
1% NP-40) with protease inhibitors. The mixture was cleared by cen-
trifugation at 10000 · g for 15 min. Proteins were fractionated by
SDS–PAGE, transferred onto Immobilon-P membranes (Millipore).
For Western blots, the mouse anti-human C21 Top1 antibody (Becton
Dickinson), or the SE2873 rabbit anti PRMT7a and PRMT7b poly-clonal antibody [6] were used. Rabbit polyclonal antibody against hu-
man PRMT7 (ab22110) was purchased from Abcam (Cambridge,
UK). Rabbit polyclonal antibodies against actin (A2066) was pur-
chased from Sigma (Saint Quentin Fallavier). Horseradish peroxi-
dase-conjugated goat anti-mouse antibodies (Amersham Biosciences)
were used as secondary antibodies. Bands were detected by ECL detec-
tion kit (Amersham Biosciences).
2.5. Topoisomerase I assays
In vitro measurements of Top1-mediated cleavage complex forma-
tion was performed as described previously, [23] using 3 0-labeled oligo-
nucleotides containing a unique Top1 site (Fig. 2A). Cleavage products
were loaded on 16% acrylamide gels containing 7 M urea. Imaging and
quantitation of dried gels were performed using a PhosphorImager
(Molecular Dynamics, Amersham Pharmacia Biotech).
2.6. Measurements of DPCs and SSBs in treated cells
DNA–protein crosslinks (DPCs) and single-strand breaks (SSB)
were measured by the alkaline elution technique [24]. Cellular DNA
was labelled with [2-14C] thymidine for 18 h followed by a 2 h chase
in fresh medium. For DPCs, cells were irradiated with 30 Gy and lysed
under non-deproteinizing conditions on protein-absorbing ﬁlters
(polyvinylchloride-acrylic copolymer ﬁlters, 0.8 lm pore size; Gelman
Sciences, Ann Harbor, MI). For SSB measurements cells were layered
on polycarbonate ﬁlter of 2 lm pore size (Nucleopore, DMF) and di-
rectly lysed in the presence of proteinase K. The DNA was eluted with
tetrapropylammonium hydroxide–EDTA (containing 0.1% SDS) at
pH 12.1. Fractions were collected over 15 h and processed according
to standard protocols [24].3. Results
3.1. Downregulation of PRMT7a and PRMT7b expressions and
sensitivity of DC-3F cells to CPT
In order to investigate the eﬀect of PRMT7a and PRMT7b
downregulation on CPT sensitivity, we stably transfected DC-
3F hamster cells with the empty vector or with the vector con-
taining the GSE1 sequence. Few clones containing either the
empty vector or the GSE1 were selected and checked for
PRMT7a and PRMT7b protein expression. The two clones
having the highest (clone 3) and the lowest expression (clone
13) were retained for the rest of the study (Fig. 1A). In clone
13, PRMT7a and PRMT7b levels were reduced by approxi-
mately six-fold for PRMT7a, and three- to four-fold for
PRMT7b as compared to clone 3. CPT sensitivity was then
compared between clone 3 and 13 by clonogenic assay as indi-
cated in Section 2 (Fig. 1B). Counting of the surviving clones
showed that clone 3 was the most resistant and clone 13 the
most sensitive. When compared to clone 3, there was an
approximately four-fold reduction in the number of surviving
clones for clone 13 (3.9 ± 0.23) for the highest CPT concentra-
tion. The eﬀect of GSE1 on CPT-induced apoptosis was also
studied by ﬂow cytometry (Fig. 1D). Cells containing the
empty vector or GSE1 were treated with increasing concentra-
tions of CPT for 24 h and labeled with TMRM in order to
evaluate the mitochondrial depolarization. The results showed
a moderate but signiﬁcant increase in the amount of apoptotic
cells in DC-3F cells containing GSE1 as compared to control
cells, which is consistent with cell survival data. Together,
these results conﬁrm that GSE1-induced downregulation of
PRMT7a and b sensitizes DC-3F cells to CPT.
3.2. Eﬀects of GSE1 on Top1-mediated cleavage complex
formation
We then investigated whether GSE1-induced CPT hypersen-
sitivity was linked to a change in Top1-mediated DNA dam-
Fig. 1. (A) Expression of the two hamster isoforms of PRMT7 (PRMT7a and PRMT7b) in DC-3F clones stably transfected with either the empty
vector pLNCX (clone 3) or with pLNCX/GSE1 (clone 13). Quantitations of the bands were performed with the Image J software and normalized
against a-tubulin. (B) CPT cytotoxicity in clones 3 and 13. Clonogenic assays were performed following 24 h treatment with 1 or 10 lM CPT. For
each clone, 500 untreated cells were plated as seeding controls. (C) Quantitation of clonogenic assays following a 24 h treatment with 10 lM CPT.
Results are expressed as a percentage of surviving clones containing the empty vector (clone 3) relative to clones expressing the GSE1 (clone 13) and
are the means ± S.D. of three independent experiments. (D) CPT-induced apoptosis in DC-3F control cells (closed bars) or cells expressing GSE1
(hatched bars). Cells were treated with indicated concentrations of CPT for 24 h and apoptosis was assessed by measuring the mitochondrial
depolarisation by TMRM in the presence of 20 lM verapamil, as described in Section 2. Experiments were performed in triplicate and the results are
expressed as means ± S.D. *P < 0.05.
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and found no diﬀerence between clone 3 and 13 (Fig. 2A).
Using nuclear extracts of each clone we compared the ability
of Top1 to form enzyme–DNA cleavage complexes in vitro
using a standard oligonucleotide assay. We found that nuclear
extracts from clone 3 and 13 induced a comparable amount of
Top1–cleavage complexes in the presence of 10 lM CPT
(Fig. 2B and C). We also used the standard alkaline elution
technique to measure the amount of single-strand breaks
(SSB) or DNA–protein cross-links (DPC) induced by CPT,which directly reﬂect the amount of Top1–DNA cleavage com-
plexes that are formed in treated cells (Fig. 3). No signiﬁcant
diﬀerence in SSB or DPC formation was found between clone
3 and 13 (Fig. 3A and B, respectively). Because a diﬀerence in
cytotoxicity could also result from a diﬀerence in reversal and/
or repair of the Top1-induced DNA damage, we also com-
pared the reversal/repair of CPT-induced SSB after drug with-
drawal. Again, no diﬀerence could be observed between clone
3 and 13 (Fig. 3C). Together, these results indicate that hyper-
sensitivity of clone 13 is not related to a quantitative or a qual-
Fig. 2. Top1 catalytic activity of cleavage/religation is not altered by the expression of GSE1. (A) Immunoblot analysis for Top1 in clone 3 (pLNCX)
or clone 13 (GSE1). Whole cell extracts (Total) or nuclear extracts (N.E.) were separated by SDS–PAGE and immunoblotting was performed using
the C21 Top1 monoclonal antibody. (B) In vitro measurements of Top1–DNA cleavage complexes have been performed using a 3 0-labeled (A*)
oligonucleotide containing a unique Top1 cleavage site (arrowhead). Assays were performed in the presence of 10 lM CPT and increasing
concentrations of nuclear extracts from clone 3 (pLNCX) or clone 13 (GSE1). Top1: Puriﬁed human recombinant Top1. (C) Quantitation of the gel
shown in panel B.
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or PRMT7b exert a downstream regulation of the signaling
pathway of CPT-induced DNA damage.
3.3. Eﬀects of PRMT7a and/or b overexpression on CPT
sensitivity
We then studied whether overexpression of PRMT7a and/or
PRMT7b could also alter DC-3F cells sensitivity to CPT.
First, PRMT7a and PRMT7b overexpression was studied in
DC-3F cells by transfection with the pSV IRES Neo/p78,
pSV IRES Neo/p82. Transfection with the pSV IRES Neo/
p78 induced almost exclusively the overexpression of the a iso-
form with an approximate 10-fold increase as compared to
control cells transfected with the pSV IRES Neo empty vector
(Fig. 4A). Conversely, cells transfected with the pSV IRES
Neo/p82 plasmid resulted in an approximately seven-fold over-
expression of both PRMT7a and b isoforms as compared to
control cells, respectively (Fig. 4A). When these cells were trea-
ted with CPT (10 lM, 24 h) no diﬀerence in survival could be
evidenced as compared to control cells (Fig. 4B). This demon-
strates that overexpression of either isoform of PRMT7 does
not aﬀect DC-3F cell sensitivity to CPT.Similar experiments were conducted in DC-3F/9-OH-E cells
which are resistant to 9-OH-E and are characterized by a two-
to three-fold reduction in PRMT7a and b isoforms [6]. Fig. 5A
shows the results of PRMT7a and/or b overexpression in DC-
3F/9-OH-E cells. Transfection of DC-3F/9-OH-E cells with
pSV IRES Neo/p78 resulted in an8-fold increase in PRMT7a
as compared to control cells. This overexpression was accom-
panied to a 2-fold increase in cell survival (Fig. 5B) and a
50% decrease in CPT-induced apoptosis (Fig. 5C). Transfection
of DC-3F/9-OH-E cells with pSV IRES Neo/p82 resulted in
both PRMT7a (8-fold) and b (10-fold) overexpression as
compared to control cells (Fig. 5A), and was accompanied by
a rather modest (1.4-fold) increase in cell survival (Fig. 5B)
and a 50% reduction in mitochondrial depolarization induced
by CPT (Fig. 5C). Thus, our results show that it is possible to
increase the resistance of DC-3F/9-OH-E cells to CPT by
restoring the expression levels of PRMT7a isoform and to a
much lower extent of the b isoform. Since overexpression of
PRMT7a and/or b does not aﬀect the cellular sensitivity to
DC-3F cells with ‘‘physiological’’ levels of both isoforms, our
data further suggest that the cellular target of PRMT7 is the
limiting factor that is critical for CPT sensitivity.
Fig. 3. GSE1 expression does not alter the formation of single-strand breaks (SSB), DNA–protein cross-links (DPC), or the reversal of DNA strand
breaks. SSB (A) or DPC (B) were measured by alkaline elution after 2 h treatment with CPT. Closed symbols: clone 13; opened symbols: clone 3. (C)
Cells were treated with 1 lM CPT for 1 h and SSB were measured by alkaline elution either immediately after treatment (squares) or after 2 h
(triangles) or 4 h (circles) incubation in drug-free medium (Rev). Closed symbols: clone 13; opened symbols: clone 3.
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human cells
It was previously shown that GSE1 was acting as a antisense
oligonucleotide and was leading to a reduction of the level of
both isoforms of PRMT7 in DC-3F hamster cells [6]. In hu-
man cells, only one form of PMRT7 can be detected. We then
veriﬁed whether downregulation of the human PMRT7 could
also sensitize tumor cells to CPT. HeLa cells were then trans-
fected with either non-targeting siRNA or siRNA directed
against PRMT7 (Fig. 6). Forty-eight hours following transfec-
tion cells were treated with DMSO or with 0.01 or 0.1 lMCPT
for 24 h and survival was assessed by standard clonogenic as-
says. The results clearly show that downregulation of PMRT7
confers a higher sensitivity of HeLa cells to CPT as compared
to control cells treated with non-targeting siRNAs, with an
approximate eight-fold diﬀerence for a drug concentration of
0.1 lM. These results are in accordance with what we observed
in DC-3F cells and further conﬁrm the importance of PMRT7
protein levels in the cellular sensitivity to CPT. They also sug-
gest that human PRMT7 could be used as a target to potenti-
ate the cellular response to CPT derivatives used in the clinic.Fig. 4. PRMT7 overexpression does not aﬀect DC-3F cells sensitivity
to CPT. (A) DC-3F control cells (EV) or cells overexpressing PRMT7a
(a) and/or PRMT7b (b) were checked 48 h following transfections by
immunoblotting using 80 lg of total cell extracts. (B) Eﬀects of
PRMT7a (a) and/or PRMT7b (b) overexpression on CPT-induced
cytotoxicity. Clonogenic assays were performed following CPT treat-
ment (10 lM, 24 h) as described in Fig. 1. For each condition, 500
untreated cells were plated as seeding controls.4. Discussion
The selection of genetic suppressor elements was successfully
used to identify new genes involved in the sensitivity to various
DNA-damaging agents [9,11,25,26]. Using this methodology,
11 GSEs that could individually confer a resistant phenotype
of DC-3F hamster cells to the Top2 inhibitor 9-hydroxyellipti-
cine were isolated [6]. Among them, GSE1 was shown to inhi-
bit the expression of p77 and p82, two hamster isoforms of a
Fig. 5. Restoration of PRMT7 expression induces CPT resistance in
DC-3F/9OH-E cells. (A) DC-3F/9-OH-E control cells (EV) or cells
overexpressing PRMT7a (a) and/or PRMT7b (b) were checked 48 h
following transfections by immunoblotting using 80 lg of total cell
extracts. (B) Eﬀects of PRMT7a (a) and/or PRMT7b (b) overexpres-
sion on CPT-induced cytotoxicity. Clonogenic assays were performed
following CPT treatment (10 lM, 24 h) as described in Fig. 1. For each
condition, 500 untreated cells were plated as seeding controls. (C)
Eﬀects of PRMT7a and/or PRMT7b overexpression in DC-3F/9-OH-
E cells on CPT-induced apoptosis. DC-3F/9-OH-E control cells (EV)
or cells expressing PRMT7a (a) or PRMT7b (b) were treated with
1 lMCPT for 24 h and mitochondrial depolarization was measured as
described in Section 2. Results are the means ± S.D. of three
independent experiments.
Fig. 6. Eﬀects of downregulation of PRMT7 on the sensitivity of
HeLa cells to CPT. (A) Cells were transfected with either non-targeting
siRNA (closed bars) or with siRNAs against PRMT7 (open bars) and
treated 48 h later by the indicated concentrations of CPT for 24 h. The
results are expressed as percentages of surviving clones relative to
untreated cells and are the means ± S.D. of three independent
experiments. *P < 0.01. (B) Silencing of PRMT7 was checked by
immunoblotting using b-actin as a loading control.
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PRMT7a and PRMT7b [27]. Downregulation of PRMT7a
and PRMT7b by GSE1 conferred a resistant phenotype to 9-
OH-E, etoposide and cisplatin. Interestingly, it could also con-
fer a hypersensitivity to other DNA damaging agents such as
UV-irradiation, bleomycin and CPT [6]. This suggested a gen-
eral regulatory role of PMRT7 in DNA damage response as
previously reported for other PRMTs for the regulation of sig-
nal transduction [28–31] and chromatin remodeling [17]. Using
DC-3F stably transfected clones we show that downregulation
of PRMT7a and b by six- and four-fold, respectively, as com-
pared to the control clone, induced a four-fold increase in cell
sensitivity to CPT which is, at least in part, due to a increase in
apoptosis. From our data, it is also very clear that this eﬀect
could not be attributable to a diﬀerence in Top1 content or
its ability to form DNA–enzyme cleavage complexes in treated
cells. Moreover, no signiﬁcant diﬀerence could be observed in
the reversal and/or repair of CPT-induced single-strand breaks
following drug removal. This suggests that the regulation ofCPT sensitivity by PRMT7 in DC-3F cells occurs downstream
from Top1–cleavage complexes formation.
We also showed that overexpression of PRMT7 isoforms did
not aﬀect DC-3F cell sensitivity to CPT, whereas it rendered
DC-3F/9-OH-E cells more resistant to the drug. These results
suggest the existence of a ‘‘physiological’’ level of PRMT7 iso-
forms which is necessary for optimal methylation of their spe-
ciﬁc substrates. In this context, it is possible that lowering the
amount of PRMT7 isoforms in DC-3F cells would induce a
decrease in methylation of these substrates, resulting in an in-
creased sensitivity to CPT. On the contrary, overexpression of
PRMT7 isoforms in DC-3F cells where the amount of enzymes
is already optimum, would not result in a change in the
amount of methylated substrates, which could explain why
no change in CPT sensitivity was observed. In DC-3F/9-OH-
E cells however, where PRMT7a and b levels are reduced by
two- to three-fold as compared to parental DC-3F cells [6],
overexpression of the two isoforms would restore a ‘‘physio-
logical’’ level of enzymes resulting in increased resistance of
these cells to CPT. Whether both isoforms are involved in this
process remains to be elucidated, but the fact that PRMT7a
cannot locate to the nucleus and does not methylate the same
substrates as PRMT7b in vitro [27] could possibly indicate that
each isoform may have a diﬀerent implication in the regulation
of CPT sensitivity in DC-3F cells. In human cells, however,
only one PRMT7 has been detected. Its sequence is highly sim-
ilar to the alpha isoform of the hamster enzyme [27]. We show
here that siRNA-mediated downregulation of the human
PRMT7 could also sensitize HeLa cells to CPT.
Altogether our results demonstrate that downregulation of
PRMT7 expression can sensitize cells to the Top1 inhibitor
camptothecin without altering the formation and/or the
V. Verbiest et al. / FEBS Letters 582 (2008) 1483–1489 1489‘‘reversal’’ of Top1–DNA cleavage complexes. Rather, they
suggest that modulation of the cellular sensitivity to CPT is
due to a deregulation of the signaling pathways downstream
from Top1–DNA cleavage complexes, by a mechanism which
remains to be investigated. It could likely include a deregula-
tion of the methylation of PRMT7 substrates such as histones
H4 or H2A [19] or interaction with other regulatory factors
such as the CTCFL (CCCTC-binding factor like) protein, a
testis-speciﬁc protein associated with epigenetic reprogram-
ming events [21]. On a clinical point of view, our study also
conﬁrm that human PRMT7 could be used as a target for
the potentiation of CPT derivatives which are widely used in
the treatment of cancers.
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